

MIGRAINE CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISTS IV VYEPTI (eptinezumab-jjmr)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Migraine

AND ALL of the following:

1. Used for the prevention of migraines
2. Patient has **ONE** of the following:
 - a. Patient has taken a preventative CGRP medication in the past or is switching from another preventative CGRP medication
 - b. Patient has had an inadequate treatment response, intolerance, or contraindication to at least **TWO** of the following prophylactic agents:
 - i. Divalproex sodium/valproate sodium (Depakote, Depakote ER)
 - ii. Topiramate (Topamax)
 - iii. Tricyclic antidepressants: amitriptyline (Elavil), nortriptyline (Pamelor)
 - iv. Serotonin-norepinephrine reuptake inhibitors: venlafaxine (Effexor XR), duloxetine (Cymbalta)
 - v. Beta-blockers: atenolol, metoprolol, nadolol, propranolol, timolol
3. Patient has **ONE** of the following:
 - a. **NO** dual therapy with another CGRP antagonist (see Appendix 1)
 - b. Dual therapy with a CGRP antagonist for acute treatment of migraine if **ONE** of the following applies:
 - i. Patient has completed an adequate 3-month trial of at least 2 migraine preventative CGRP antagonists (i.e., Aimovig, Ajovy, Emgality, Nurtec ODT, Qulipta and Vyepti)
 - ii. Patient has completed an adequate 3-month trial of a migraine preventative CGRP antagonist in combination with a triptan agent

MIGRAINE CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISTS IV VYEPTI (eptinezumab-jjmr)

Prior - Approval Limits

Quantity

Drug	Quantity
Vyepti single-dose vial 100 mg/mL	3 vials per 90 days

Duration 6 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Migraine

AND ALL of the following:

1. Used for prevention of migraine
2. Documented decrease in migraine days from baseline **OR** improvement in daily activities due to the reduction of debilitating migraines
3. Patient has **ONE** of the following:
 - a. **NO** dual therapy with another CGRP antagonist (see Appendix 1)
 - b. Dual therapy with a CGRP antagonist for acute treatment of migraine if **ONE** of the following applies:
 - i. Patient has completed an adequate 3-month trial of at least 2 migraine preventative CGRP antagonists (i.e., Aimovig, Ajovy, Nurtec ODT, Emgality, Qulipta and Vyepti)
 - ii. Patient has completed an adequate 3-month trial of a migraine preventative CGRP antagonist in combination with a triptan agent

Prior - Approval *Renewal* Limits

Quantity

Drug	Quantity
Vyepti single-dose vial 100 mg/mL	3 vials per 90 days

Duration 12 months



**BlueCross
BlueShield**

Federal Employee Program.

MIGRAINE CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISTS IV VYEPTI (eptinezumab-jjmr)

Appendix 1 - List of CGRP Antagonists

Generic Name	Brand Name
atogepant	Qulipta
eptinezumab-jjmr	Vyepti
erenumab-aooe	Aimovig
fremanezumab-vfrm	Ajovy
galcanezumab-gnlm	Emgality
rimegepant	Nurtec ODT
ubrogepant	Ubrelvy
zavegepant	Zavzpret